ArriVent BioPharma, Inc.
No enriched coverage for $AVBP in the last 7 days.
No SEC Form 4 filings for $AVBP in the last 30 days.
See all $AVBP insider activity →ArriVent BioPharma, Inc. (AVBP) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 ArriVent BioPharma Reports Second Quarter 2026 Financial Results · Topline global pivotal Phase 3 data for firmonertinib in first-line EGFR exon 20 insertion mutant NSCLC expected 2H 2026 · ARR-217, a CDH17 targeted ADC for gastrointestinal malignancies, advanced to
Clear Street names five biotech stocks for 2H 2026 catalysts: MoonLake (MLTX) Buy, $70 target; Cullinan (CGEM) Buy, $46; Zura Bio (ZURA) Buy, $18; Arrivent (AVBP) Buy, $47; Protagonist (PTGX) Buy, $116. It cites planned clinical readouts and regulatory milestones, plus MLTX’s ~$200M offering and AVBP’s up to $250M ATM filing.
ArriVent BioPharma, Inc. (AVBP) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. false 0001868279 0001868279 2026-06-18 2026-06-18 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Repor
Recent AVBP coverage spans financial news, earnings and sector analysis.
Near-term catalysts are 2H 2026 topline for firmonertinib FURVENT and Q3 2026 first patient dosing for ARR-002, supported by $373.1M cash.
AVBP is positioned as a potential category-defining oncology winner if mid-2026 Phase 3 results are strong.
Routine annual-meeting voting results; limited direct fundamental change, but confirms governance/auditor continuity.
Near-term momentum is being reinforced by multiple upward analyst target revisions, despite a recent EPS miss.
The appointment of Brent S. Rice as Chief Commercial Officer may positively influence ArriVent BioPharma's strategic direction and market perception.
alphai scores every news story that mentions AVBP with an AI model for sentiment and relevance, and aggregates insider trades from ArriVent BioPharma, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
ArriVent BioPharma, Inc. (AVBP) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 ArriVent BioPharma Reports Second Quarter 2026 Financial Results · Topline global pivotal Phase 3 data for firmonertinib in first-line EGFR exon 20 insertion mutant NSCLC expected 2H 2026 · ARR-217, a CDH17 targeted ADC for gastrointestinal malignancies, advanced to
7 min readClear Street names five biotech stocks for 2H 2026 catalysts: MoonLake (MLTX) Buy, $70 target; Cullinan (CGEM) Buy, $46; Zura Bio (ZURA) Buy, $18; Arrivent (AVBP) Buy, $47; Protagonist (PTGX) Buy, $116. It cites planned clinical readouts and regulatory milestones, plus MLTX’s ~$200M offering and AVBP’s up to $250M ATM filing.
7 min readArriVent BioPharma, Inc. (AVBP) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. false 0001868279 0001868279 2026-06-18 2026-06-18 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Repor
3 min readArriVent BioPharma (NASDAQ:AVBP) shares rose 9.7% mid-day Thursday, trading up to $33.00 and last at $32.68 versus a prior close of $29.78. Mid-day volume was 194,230 shares, down 61% from the average. Analysts cited include B. Riley, Truist, HC Wainwright, Oppenheimer, and others; consensus is “Moderate Buy” with an average $43.38 target. The company reported May 11 EPS of -$0.96, missing estimates of -$0.88.
4 min readNEWTOWN SQUARE, Pa., Sept. 22, 2025 ( GLOBE NEWSWIRE ) -- ArriVent BioPharma, Inc. ( Company or ArriVent ) AVBP, a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced the appointment of Brent S.
2 min readNEWTOWN SQUARE, Pa., Sept. 22, 2025 ( GLOBE NEWSWIRE ) -- ArriVent BioPharma, Inc. ( Company or ArriVent ) ( Nasdaq: AVBP ) , a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced the appointment of Brent S.
2 min readU.S. stock futures were higher this morning, with the Dow futures gaining around 0.2% on Wednesday. Shares of Centene Corporation CNC fell sharply in today's pre-market trading after the health care company withdrew its guidance for 2025.
3 min readNEWTOWN SQUARE, Pa., July 01, 2025 ( GLOBE NEWSWIRE ) -- ArriVent BioPharma, Inc. ( "ArriVent" ) ( Nasdaq: AVBP ) , a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced the pricing of an underwritten public ...
2 min read16.0 months median progression free survival ( mPFS ) with firmonertinib 240 mg by blinded independent central review ( BICR ) in first-line patients ...
3 min readVirtual webinar on June 23, 2025 at 8:00 am ET Virtual webinar on June 23, 2025 at 8:00 am ET ...
2 min read
